Asco 2022 – Merus gets some competition
Response rates with zenocutuzumab hold up, but Elevation Oncology’s rival project looks similar.
After US approval Aveo faces a monumental task
Aveo gets Fotivda over the line in the US, but the market celebration looks misplaced.
Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Asco 2020 – abstract dump triggers first moves
An early look at data from the huge cancer conference boosts Allogene and Immunogen, while Arvinas and Cytomx suffer.
Upcoming events – Aveo awaits tivo's death sentence and Glaxo goes long
Aveo will soon find out whether Fotivda has a future, while Glaxo awaits data with an even longer-lasting HIV doublet.
Déjà vu for Aveo and tivozanib
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
